DNA VaccinesMark W. Saltzman, Hong Shen, Janet L. Brandsma Springer Science & Business Media, 2008 M02 2 - 384 pages In the early 1990s, almost 200 yr after Edward Jenner demonstrated the effectiveness of the smallpox vaccine, a new paradigm for vaccination emerged. The conventional method of vaccination required delivery of whole pathogens or structural subunits, but in this new approach, DNA or genetic information was administered to elicit an immunological response. Once it was observed that plasmid DNA delivered in vivo led to production of an encoded transgene (1), two ground-breaking studies demonstrated that immunological responses could be generated against antigenic transgenes via plasmid DNA delivered by DNA vaccination (as this approach is called) (2,3). The appe- ance of this new vaccination strategy coincided with advances in molecular biology, which provided new tools to study and manipulate the basic elements of an organism’s genome and also could also be applied to the design and production of DNA vaccines. DNA Vaccines is a major updated and enhancement of the first edition. It reviews state-of-the-art methods in DNA vaccine technology, with chapters describing DNA vaccine design, delivery systems, adjuvants, current appli- tions, methods of production, and quality control. Consistent with the approach of the Methods in Molecular Medicine series, these chapters contain detailed practical procedures on the latest DNA vaccine technology. The enthusiasm for DNA vaccine technology is made clear by the number of research studies published on this topic since the mid-1990s. |
From inside the book
Results 1-5 of 88
Page ii
... Human Papillomaviruses : Methods and Protocols , edited by Clare Davy and John Doorbar , 2005 118. Antifungal Agents : Methods and Protocols , edited by Erika J. Ernst and P. David Rogers , 2005 117. Fibrosis Research : Methods and ...
... Human Papillomaviruses : Methods and Protocols , edited by Clare Davy and John Doorbar , 2005 118. Antifungal Agents : Methods and Protocols , edited by Erika J. Ernst and P. David Rogers , 2005 117. Fibrosis Research : Methods and ...
Page vi
... humans to produce an immune response. Part II describes methods for DNA delivery, covering both the wide range of ... human papillomavirus (HPV), and infectious diseases caused by HIV, as well as neoplastic diseases such as melanoma ...
... humans to produce an immune response. Part II describes methods for DNA delivery, covering both the wide range of ... human papillomavirus (HPV), and infectious diseases caused by HIV, as well as neoplastic diseases such as melanoma ...
Page vii
Mark W. Saltzman, Hong Shen, Janet L. Brandsma. successful in humans. In one study, intramuscular injection of DNA ... human disease with attributes that make it suit- able for both developed and developing nations. W. Mark Saltzman ...
Mark W. Saltzman, Hong Shen, Janet L. Brandsma. successful in humans. In one study, intramuscular injection of DNA ... human disease with attributes that make it suit- able for both developed and developing nations. W. Mark Saltzman ...
Page viii
... human cervical high - grade cervical intraepithelial neoplasia with microparticle - deliv- ered human papillomavirus 16 E7 plasmid DNA . Am . J. Obstet . Gynecol . 188 , 916–926 . 13. Wang , R. , Epstein , J. , Charoenvit , Y. , et al ...
... human cervical high - grade cervical intraepithelial neoplasia with microparticle - deliv- ered human papillomavirus 16 E7 plasmid DNA . Am . J. Obstet . Gynecol . 188 , 916–926 . 13. Wang , R. , Epstein , J. , Charoenvit , Y. , et al ...
Page 4
... human papil- lomavirus (HPV) L1-based virus-like particle vaccine have shown complete protection of vaccinated women against infection after a median follow-up time of 17 mo (3). Certain antibodies may be useful for treating human ...
... human papil- lomavirus (HPV) L1-based virus-like particle vaccine have shown complete protection of vaccinated women against infection after a median follow-up time of 17 mo (3). Certain antibodies may be useful for treating human ...
Contents
Montgomery and Kristala Jones Prather 3 Vaccination With Messenger RNA | 11 |
A Stress ProteinFacilitated Antigen Expression System | 41 |
Weiwen Jiang Charles F Reich and David S Pisetsky | 55 |
Delivery of DNA Vaccines Using Electroporation | 73 |
and Methodology | 83 |
Sylvia van Drunen Littelvan den Hurk Shawn Babiuk | 91 |
for DNA Vaccine Delivery | 107 |
Subcellular Trafficking Pathways by Indirect | 127 |
Sandra Scheiblhofer Richard Weiss Maximilian Gabler | 221 |
Immunological Responses of Neonates and Infants | 239 |
DNA Vaccines for Allergy Treatment | 253 |
Protection From Autoimmunity by DNA Vaccination | 269 |
Immune Mechanisms | 281 |
DNA VACCINE PRODUCTION PURIFICATION AND QUALITY | 293 |
Production of Plasmid DNA in Industrial Quantities According | 339 |
LargeScale Nonchromatographic Purification of Plasmid | 351 |
Adjuvant Properties of CpG Oligonucleotides in Primates | 139 |
Complexes of DNA Vaccines With Cationic Antigenic Peptides | 159 |
PrimeBoost Strategies in DNA Vaccines | 171 |
Modifying Professional AntigenPresenting Cells to Enhance | 199 |
Other editions - View all
Common terms and phrases
acid activation adjuvants antibody antigen antigen-specific APCs approx assay bacterial DNA Biojector buffer cationic CD8+ T cells cellular centrifuge chromatography clinical trials cloning codon coli concentration conjugation containing cover slips CpG motifs CpG ODN culture cytokine delivery dendritic cells detection diluted DL-DNA DNA vaccines electroporation ELISPOT encoding endotoxin enhance enzyme epitopes ethanol expression filter g/mL gene gun genomic human immune responses immunogenicity Immunol immunostimulatory Incubate induce injection Invitrogen lysate lysis macaques medium Methods and Protocols MHC class mice microspheres Molecular molecules mouse mRNA needle-free neonates Note oligodeoxynucleotides oligonucleotides optimal PBMC pDNA pellet peptide plasmid DNA plate PLGA Prepare priming production protein purification Qiagen receptor recombinant Resuspend room temperature RPMI sample sequence serum solution specific sterile stimulation strategies supernatant syringe T-cell T-cell responses target tion tissue transfected tube tumor vector viral virus vitro vivo Wash µg/mL